Literature DB >> 18670458

Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment.

W Amoaku1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18670458     DOI： 10.1038/eye.2008.241

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  10 in total

1.  [Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain].

Authors:  H Heimann; Y Yang; J Wachtlin; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

Review 2.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

3.  Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration.

Authors:  R Mathew; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

4.  A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications.

Authors:  S P Kelly; A Barua
Journal:  Eye (Lond)       Date:  2011-04-29       Impact factor: 3.775

5.  Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.

Authors:  Pearse A Keane; Adnan Tufail; Praveen J Patel
Journal:  J Ophthalmol       Date:  2011-11-22       Impact factor: 1.909

Review 6.  Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Authors:  Laurent Kodjikian; Mariacristina Parravano; Andreas Clemens; Rosa Dolz-Marco; Frank G Holz; Marion R Munk; Massimo Nicolò; Federico Ricci; Rufino Silva; S James Talks; Rohini Kumar Verma; Javier Zarranz-Ventura; Sandrine A Zweifel
Journal:  Eye (Lond)       Date:  2021-04-01       Impact factor: 3.775

7.  A systematic review of clinical practice guidelines for myopic macular degeneration.

Authors:  Yanxian Chen; Xiaotong Han; Iris Gordon; Sare Safi; Gareth Lingham; Jennifer Evans; Jinying Li; Mingguang He; Stuart Keel
Journal:  J Glob Health       Date:  2022-03-26       Impact factor: 4.413

8.  Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.

Authors:  Martin Stattin; Anna-Maria Haas; Daniel Ahmed; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  Eur J Ophthalmol       Date:  2021-11-02       Impact factor: 1.922

9.  Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration.

Authors:  Youxin Chen; Fei Han
Journal:  Ther Clin Risk Manag       Date:  2012-07-11       Impact factor: 2.423

Review 10.  Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration.

Authors:  Alfredo García-Layana; Marta S Figueroa; Luis Arias; Javier Araiz; José María Ruiz-Moreno; José García-Arumí; Francisco Gómez-Ulla; María Isabel López-Gálvez; Francisco Cabrera-López; José Manuel García-Campos; Jordi Monés; Enrique Cervera; Felix Armadá; Roberto Gallego-Pinazo
Journal:  J Ophthalmol       Date:  2015-09-27       Impact factor: 1.909
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.